Back grey_arrow_rt.gif
 
HIV PrEP Pre-Exposure Prophylaxis Articles
 
null.gif
 
 
    Additional models:
     
         Feasibility of Long-Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C. - (07/27/23))
     
    PEP-in-pocket (PIP): Long-term follow-up of on demand HIV post-exposure prophylaxis: Is PEP-in-Pocket Best Option for Low-Frequency High-Risk HIV Exposure? - (10/18/23))
     
    Expanding PrEP by Embedding Navigators in High STI Testing Clinical Sites - (10/18/23))
     
    Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women - (10/16/23))
     
    Integrating Long-Acting Injectable Cabotegravir for PrEP Into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex With Men: Results From the PILLAR & EBONI Studies - (10/16/23))
     
    At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implemtentation Science Trial - (10/13/23))
     
    ---------------------------------------------------
     
  1. Trends in Oral and Injectable HIV Preexposure Prophylaxis Prescriptions in the US, 2013-2023 - (12/20/24)
     
  2. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024 - (12/20/24)
     
  3. UN Global Call LA HIV Drugs Access - (12/14/24)
     
  4. 2024 Breakthrough of the Year The long shot An injectable HIV drug with a novel mechanism shows remarkable ability to prevent infection - (12/14/24)
     
  5. Long-Acting HIV Medicines and the Pandemic Inequality Cycle - Rethinking Access - (12/14/24)
     
  6. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons, PURPOSE 2 - (12/06/24)
     
  7. Glasgow: PrEP for Women Case Discussion: On Demand 2:7 for Women Discussed - (12/04/24)
     
  8. Glasgow: PrEPping for the Future: The Era of Choice - (12/04/24)
     
  9. Glasgow: LEN PrEP PURPOSE-2 Twice-Yearly Gilead Glasgow Press Release - (11/16/24)
     
  10. Glasgow: PrEP-Associated Stigma in Europe: Findings From a Real-World Survey - (11/16/24)
     
  11. Glasgow: Cost-effectiveness and Public-Health Impact of Cabotegravir Long-Acting Injectable for HIV Pre-exposure Prophylaxis in Canada - (11/16/24)
     
  12. Glasgow: PURPOSE 1 LEN PrEP Summary - (11/16/24)
     
  13. Glasgow: Len LA PrEP PURPOSE 2 Summary - (11/16/24)
     
  14. Glasgow: Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2) - (11/16/24)
     
  15. Glasgow: Annual persistence in use of twice-yearly lenacapavir versus daily oral PrEP in the PURPOSE 1 phase 3 trial - (11/16/24)
     
  16. ID Week: Implementation and Uptake of Long-acting Injectable PrEP at Atlanta VA Healthcare System - (10/24/24)
     
  17. ID Week: Implementation and Uptake of Long-acting Injectable PrEP at Atlanta VA Healthcare System - (10/24/24)
     
  18. ID Week: Opportunities for PrEP Awareness and Engagement: A Survey among Cisgender Women Seeking Healthcare in the US - (10/24/24)
     
  19. ID Week: Improving HIV Pre-exposure Prophylaxis (PrEP) among Transgender Individuals - (10/24/24)
     
  20. ID Week: Integrating PrEP Services into a Gynecology Clinic in Alabama: A Qualitative Analysis of Key Determinants - (10/24/24)
     
  21. ID Week: Concerns and opinions of people currently or previously on oral and long acting injectable forms of HIV preexposure prophylaxis (PrEP) - (10/24/24)
     
  22. ID Week: Trajectories of Newly Initiated Pre-Exposure Prophylaxis (PrEP) Use among Priority Populations with Unmet Needs for PrEP in the USA - (10/21/24)
     
  23. ID Week: Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health Cohort - (10/21/24)
     
  24. ID Week: Missed opportunities for HIV Prevention and Treatment in People Hospitalized with Serious Injection Related Infections: The CHOICE+ Cohort - (10/21/24)
     
  25. ID Week: Week 26 Interim Analysis of Implementation and Delivery of Long-Acting Injectable Cabotegravir for PrEP in a Community Pharmacy Setting - (10/21/24)
     
  26. ID Week: Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort - (10/21/24)
     
  27. ID Week: Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic - (10/21/24)
     
  28. ID Week: Change in Healthcare Professionals' Identification, Counseling, and Adherence With Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women's Health, Primary Care, and Infectious Diseases Sites: Findings From the EBONI Study - (10/21/24)
     
  29. ID Week: PrEP Decision Factors: a CHORUS Healthcare Professional Survey - (10/21/24)
     
  30. ID Week: Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis (PrEP): A Real-World Study - (10/21/24)
     
  31. ID Week: Update on Lenacapavir for PrEP: Results from the Interim Analyses of PURPOSE 1 and PURPOSE 2 - (10/21/24)
     
  32. ID Week: Over 80% Adhere to Long-Acting CAB+RPV Despite Prior Non-Adherence - Mark Mascolini (10/21/24)
     
  33. ID Week: People With HIV in the United States (US) Switching to Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) From Oral Antiretroviral Therapy (ART) Have Numerous Real-World Benefits, Including High Adherence and Treatment Satisfaction - (10/21/24)
     
  34. ID Week: Long-acting Injectable HIV Treatment in Individuals with Adherence Challenges: - (10/21/24)
     
  35. HIVR4P The role of healthcare-related experiences in willingness and preference for long-acting injectable PrEP (LA-PrEP) among transfeminine persons in the US Transgender Women's Internet Survey and Testing (TWIST) study - (10/16/24)
     
  36. HIVR4P Gap Between Oral and Injectable PrEP Awareness in US Transgender Women - Mark Mascolini (10/16/24)
     
  37. HIVR4P Managing inflammation from STIs as an HIV prevention strategy Can Cutting STI-Linked Inflammation Prevent HIV Infection? - Mark Mascolini (10/16/24)
     
  38. HIVR4P STI Risk Falls 80% After Milan MSM Get DoxyPEP Prescription - Mark Mascolini (10/16/24)
     
  39. HIVR4P Use of HIV rapid detection tests when initiating long-acting cabotegravir for HIV prevention, within an implementation science project - (10/16/24)
     
  40. HIVR4P Acceptability, adherence, preference and safety of placebo Long-Acting Pre-exposure Prophylaxis (LA-PrEP) injections and implants for HIV-prevention in South African men: the SAMURAI study - (10/16/24)
     
  41. HIVR4P HIV PEP-in-Pocket ("PIP") facilitates the de-medicalization of HIV prevention - (10/16/24)
     
  42. HIVR4P PrEP uptake and adherence among transgender women: findings from a randomized clinical trial of a multicomponent intervention (HPTN 091) PrEP Uptake Over 85% in Big US/Brazil Transgender Woman Study - Mark Mascolini (10/16/24)
     
  43. HIVR4P Greater PrEP use in a community-based needle and syringe program versus facility-based medication for opioid use disorder program for people who use drugs in Uganda - (10/16/24)
     
  44. HIVR4P PrEP choice for women in Africa: uptake of oral PrEP and PrEP ring - (10/16/24)
     
  45. HIVR4P Patterns of PrEP use among women in the context of choice: early results from CATALYST, an implementation study offering oral PrEP and PrEP ring across five African countries - (10/16/24)
     
  46. HIVR4P Provider and client perspectives on PrEP choice: quality of PrEP choice and factors influencing its provision in the CATALYST implementation study - (10/16/24)
     
  47. HIVR4P Integration of oral and injectable PrEP services for adolescents at the community level in Sao Paulo - (10/16/24)
     
  48. HIVR4P Switching between oral and injectable pre-exposure prophylaxis (PrEP) regimens in the United States: an investigation of reasons for switching in the real world - (10/12/24)
     
  49. HIVR4P Early implementation of long-acting injectable cabotegravir for HIV prevention in a safety net primary care center in U.S. South at Grady in Atlanta - (10/12/24)
     
  50. HIVR4P Pharmacokinetic superiority of a 3-month dapivirine vaginal ring (100 mg) compared to the 1-month dapivirine vaginal ring (25 mg) - (10/12/24)
     
  51. HIVR4P Short-term combination immunotherapy with broadly neutralizing antibodies and CCR5 blockade mediates ART-free viral control in infant rhesus macaques - (10/11/24)
     
  52. HIVR4P 17-Clinic US Study Pinpoints Keys to Giving Long-Acting Injected PrEP: Overcoming Challenges Integrating Injectable PrEP Into Care: Key Strategies From The PILLAR Study - Mark Mascolini (10/11/24)
     
  53. HIVR4P High CAB-LA PrEP On-Time and Retention Rates in US Urban Safety-Net Clinic Population. SF, Ward-86 - Mark Mascolini (10/11/24)
     
  54. HIVR4P Long-acting injectable Cabotegravir (CAB-LA) pilot implementation at primary healthcare level in resource-limited settings: early real-world evidence from the USAID DISCOVER-Health Project in Zambia - (10/11/24)
     
  55. HIVR4P HIV pre-exposure prophylaxis (PrEP) access preference among men who have sex with men in China: a discrete choice experiment - (10/10/24)
     
  56. HIVR4P Phase 1 dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics and neutralization activity of PGDM1400LS in combination with VRC07-523LS and PGT121.414.LS in healthy participants without HIV (HVTN 140/HPTN 101) - (10/10/24)
     
  57. HIVR4P HIV Trends in Metropolitan US Cities from 2014-2022: Baseline For The Ending The Epidemic Initiative - (10/10/24)
     
  58. HIVR4P Early virologic success on ART following breakthrough infection on CAB-LA PrEP - Mark Mascolini (10/10/24)
     
  59. HIVR4P Gilead Lenacapavir Access Statement & Voluntary Licensing Agreement - (10/10/24)
     
  60. HIVR4P PURPOSE-2 & Other PURPOSE Studies - (10/10/24)
     
  61. HIVR4P Global racial, ethnic, and gender diversity among participants enrolled in the PURPOSE-2 trial of lenacapavir for pre-exposure prophylaxis (PrEP) - (10/10/24)
     
  62. HIVR4P Development of a long-acting biodegradable hydrogel injectable system for single or multi-purpose prevention of HIV and/or pregnancy - (10/10/24)
     
  63. HIVR4P Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender men and transgender women at elevated risk for acquiring HIV-1 - (10/10/24)
     
  64. HIVR4P Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender women at elevated risk for acquiring HIV-1 - (10/10/24)
     
  65. HIVR4P Scaling a non-human primate physiologically-based pharmacokinetic model of extended-release MK-2048 and combination MK-2048/vicriviroc (MK-2048A) intravaginal rings into humans using phase 1 MTN-027 and MTN-028 studies - (10/09/24)
     
  66. HIVR4P Weekly oral prophylaxis with MK-8527 protects rhesus macaques from rectal challenge with simian-human immunodeficiency virus - (10/09/24)
     
  67. HIVR4P ViiV HEALTHCARE TO TRIPLE ANNUAL SUPPLY OF LONG-ACTING HIV PREP FOR LOW- AND MIDDLE-INCOME COUNTRIES - (10/06/24)
     
  68. HIVR4P Preferences for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among transfeminine persons in the United States: results from the Transgender Women's Internet Survey and Testing (TWIST) study - (10/06/24)
     
  69. HIVR4P Preferences for telePrEP among people who access HIV self-testing in Philadelphia - (10/06/24)
     
  70. HIVR4P Implementing long-acting cabotegravir for HIV Pre-Exposure Prophylaxis in a large academic hospital-based urban HIV clinic - (10/06/24)
     
  71. HIVR4P Examples of studies - CATALYST South Africa - (10/06/24)
     
  72. HIVR4P Examples of studies - DCE results on service delivery preferences - (10/06/24)
     
  73. HIVR4P Examples of studies - Project PrEP - (10/06/24)
     
  74. HIVR4P Implementing PrEP Choice: Experiences from South Africa - (10/06/24)
     
  75. HIVR4P History of injectable contraception was associated with women's willingness to use long-acting injectable PrEP: findings from US women across nine cities - (10/06/24)
     
  76. HIVR4P Characterizing the Levels of Knowledge, Attitudes, and Behaviors Regarding the Use and Risks Associated with Oral HIV-1 Pre-Exposure Prophylaxis (PrEP) Among People Prescribed PrEP in Canada - (10/06/24)
     
  77. HIVR4P Understanding preferences for pre-exposure prophylaxis (PrEP) among people who would benefit from PrEP in the United States - (10/06/24)
     
  78. HIVR4P Interest in long-acting PrEP modalities among women in the United States with a history of injectable medication use: findings from the MACS/WIHS combined cohort study - (10/06/24)
     
  79. HIVR4P Safety, Pharmacokinetics, and Degradation of Ultra-Long-Acting Injectable, Biodegradable, and Removable In-Situ Forming Implant with Cabotegravir for HIV Prevention - (10/06/24)
     
  80. Latino PrEP Barriers "Why Not Just go on PrEP?": A Study to Inform Implementation of an HIV Prevention Intervention Among Hispanic/Latino Men Who Have Sex With Men in the Northeastern United States - (09/09/24)
     
  81. IAS: The DoxyPEP Debate: To DoxyPEP or not to DoxyPEP? - (08/26/24)
     
  82. IAS: Phase 1, open-label study to evaluate the drug interaction between MK-8527, an HIV-1 nucleoside reverse transcriptase translocation inhibitor, and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females - (08/06/24)
     
  83. IAS: Long-acting oral PrEP is preferred to injections: findings from an online sample of American gay, bisexual, and other men who have sex with men - (08/06/24)
     
  84. IAS: Early experiences with usage of injectable cabotegravir (CAB-LA) among Kenyan and Ugandan adults participating in the SEARCH Dynamic Choice HIV Prevention trial: a qualitative study....self & external stigma, convenience, feeling healthy - (08/03/24)
     
  85. IAS: Pre-Exposure Prophylaxis product choice of participants in HPTN 083 - (08/03/24)
     
  86. IAS: Changes in sexual behavior among adolescent girls receiving long-acting injectable cabotegravir for HIV prevention: the HPTN 084-01 study - (08/03/24)
     
  87. IAS: CAB-LA for PrEP Earns High Satisfaction Rates (90%) in Rural Kenya and Uganda - Mark Mascolini (08/03/24)
     
  88. IAS: (Implants) Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort - (08/02/24)
     
  89. IAS: Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort - (08/01/24)
     
  90. Dolutegravir with recycled nucleoside reverse transcriptase inhibitors maintains better viral suppression than protease inhibitor based antiretroviral therapy over 144 weeks: VISEND Trial - (08/01/24)
     
  91. IAS: Influencers and Decision-Making Factors for Choosing Injectable PrEP Among Men Who Have Sex With Men and Transgender Men in the United States - (08/01/24)
     
  92. IAS: Location preferences for accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men who have sex with men (MSM) in the U.S currently using daily-oral PrEP - (08/01/24)
     
  93. IAS: Need for Improved HIV Testing Prior to and During Pre-Exposure Prophylaxis with Cabotegravir Long-Acting Injections in Routine Clinical Care in the United States: Low Rates of HIV Tesing - (08/01/24)
     
  94. IAS: Only 9% PrEP Use Among Transfeminine Persons: HIV pre-exposure prophylaxis awareness, willingness, and use among transfeminine persons with high likelihood of HIV in the United States: results from the Transgender Women's Internet Survey and Testing (TWIST) - (08/01/24)
     
  95. IAS: "The simplest way to go:" A mixed methods analysis of why women who inject drugs selected long-acting injectable cabotegravir instead of daily oral PrEP.....95% of women initiated CAB Lai PrEP !!! - (07/31/24)
     
  96. IAS: Increased cardiovascular risk in perinatally HIV-acquired adolescents (PHIV) may linked to proinflammatory NK cells - (07/31/24)
     
  97. IAS: Real-World Adherence of HIV-1 Oral Pre-Exposure Prophylaxis Regimens in the USA: A Group-Based Trajectory Modeling Approach
  98. IAS: Initial evaluation of injectable cabotegravir (CAB-LA) safety during pregnancy in the HPTN 084 open-label extension - (07/30/24)
     
  99. IAS: Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy - (07/30/24)
     
  100. IAS: Doxycycline PrEP prevents STIs without affecting vaginal bacterial flora in female sex workers in Tokyo - (07/28/24)
     
  101. IAS: Evaluation of long-acting cabotegravir (CAB-LA) pharmacokinetics during pregnancy: a sub-study analysis of the HPTN 084 open label extension study - (07/28/24)
     
  102. IAS: High Interest in LA PrEP Among MSM in Europe Survey - Intention to use long-acting PrEP among MSM in Europe -results from the PROTECT survey from Spain, Italy, Germany, France and the United Kingdom - (07/28/24)
     
  103. IAS: STI testing rates among PrEP users randomized to 3-monthly (standard of care) or 6-monthly monitoring within the EZI-PrEP trial, the Netherlands: preliminary results - no difference in STIs between 6 vs 3 months visits - (07/28/24)
     
  104. IAS: Knowledge, awareness, feasibility, and acceptability of long-acting Cabotegravir for HIV prevention: results from the SEARCH Dynamic Choice HIV prevention trial - (07/28/24)
     
  105. IAS: Centering Community Leadership with PURPOSE: Inclusion of Adolescents, Cisgender Women, and Pregnant and Lactating Individuals in a Phase 3 Clinical Trial Evaluating Lenacapavir and Emtricitabine/Tenofovir Alafenamide for PrEP - (07/28/24)
     
  106. IAS: Twice-Yearly Lenacapavir or Daily Emtricitabine/Tenofovir Alafenamide for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study - (07/28/24)
     
  107. IAS: DoxyPrEP Cuts STI Rate in FSW Without Fueling Other Infections - Mark Mascolini (07/27/24)
     
  108. IAS: A pilot, randomized controlled trial of doxycycline pre-exposure prophylaxis versus placebo for prevention of bacterial sexually transmitted infections in men who have sex with men living with HIV - (07/27/24)
     
  109. IAS: Antimicrobial resistance (AMR) in Neisseria gonorrhoeae (GC) infections among MSM on Doxycycline post-exposure prophylaxis. - (07/24/24)
     
  110. The relationship between anti-LGBTQ+ legislation and HIV prevention among sexual and gender minoritized youth - (05/23/24)
     
  111. Impact of HIV pre-exposure prophylaxis prescriptions on HIV diagnoses in New York city: disparities in new HIV diagnosis - (05/23/24)
     
  112. EuroHIV-HepMtg2024: Acute Hepatitis B Infections after Reducing ART among Vaccinated Patients Living with HIV: HBV "PrEP-effect" of TDF/FTC? - (05/23/24)
     
  113. Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment & Prevention for People Experiencing Homelessness - (04/03/24)
     
  114. CROI: EHE "May not be feasible in many US cities" - Charting Achievable Milestones for HIV Care Enhancement and Prevention in the US Through 2035 - (04/02/24)
     
  115. CROI: First Case of HIV Seroconversion With Emergence of InSTI Resistance on CAB-LA PrEP in Routine Care - (04/02/24)
     
  116. CROI: HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women - (04/02/24)
     
  117. CROI: A Randomized Trial Switching Adults ≥ 60 Years Old From First-Line ART to B/F/TAF: Week 48 Results - (03/28/24)
     
  118. CROI: Cabotegravir Population Pharmacokinetic Analysis of Adults & Adolescents Living with HIV or at Risk for HIV Receiving PrEP - (03/27/24)
     
  119. CROI: Why Is Cabotegravir Rollout So Slow? - (03/27/24)
     
  120. CROI: HIV Post-exposure Prophylaxis (PEP) Prescription Trends (underutilized) - United States, 2013-2022 - (03/27/24)
     
  121. CROI: PEP2PrEP: an effective HIV risk-reduction strategyn - (03/27/24)
     
  122. CROI: Randomized Trial Shows Huge Uptake Success of HIV Prevention Choices in Kenya, Uganda - (03/22/24)
     
  123. CROI: US States With More PrEP Coverage See Bigger Drops in HIV Diagnoses - Mark Mascolini (03/18/24)
     
  124. CROI: Safety Study of Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Early Pregnancy - (03/18/24)
     
  125. CROI: Strong Oral PrEP Uptake and Persistence in 3000 African Girls and Young Women in INSIGHT Cohort - Mark Mascolini (03/18/24)
     
  126. CROI: < HIV Incidence in Users of HIV Preexposure Prophylaxis in Australia: A Whole-of-Population Analysis - (03/18/24)
     
  127. CROI: HIV incidence in users of HIV preexposure prophylaxis in Australia: a whole-of-population analysis - Mark Mascolini (03/18/24)
     
  128. CROI: Associations between a polygenic risk score for Alzheimer's disease and brain integrity in HIV - (03/18/24)
     
  129. CROI: Doxy-PEP Associated with Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco.....increase in gonorrhea after SF Guidelines Oct 2022 - (03/18/24)
     
  130. CROI: Doxy-PEP Effectiveness in Men Who Have Sex with Men (MSM) and Transgender Women (TGW) on HIV PrEP - (03/18/24)
     
  131. CROI: Doxycycline Post-Exposure Prophylaxis (DoxyPEP): High uptake and Significant Decline in STIs after Clinical Implementation - (03/18/24)
     
  132. CROI: Randomized Trial Shows Huge Uptake Success of HIV Prevention Choices in Kenya, Uganda - Mark Mascolini (03/18/24)
     
  133. CROI: Phone calls for PrEP persistence in Kenyan women in postabortal care: a cluster randomized trial. - Mark Mascolini (03/12/24)
     
  134. CROI: PrEP Non-Persistence and New HIV Diagnoses: A Real-World Analysis of >120,000 People Prescribed PrEP - (03/12/24)
     
  135. CROI: Safety of dapivirine vaginal ring and oral PrEP for HIV prevention in the second trimester. - Mark Mascolini (03/12/24)
     
  136. CROI: CHANGES IN HIV PREP AWARENESS & USE AMONG PWID IN 19 U.S. CITIES, 2018 & 2022 ....very low PrEP use - (03/12/24)
     
  137. CROI: Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083 - (03/12/24)
     
  138. CROI: Healthcare Staff Acceptability and Feasibility of Telehealth Delivery of Cabotegravir for PrEP - (03/12/24)
     
  139. CROI: Interest in Long-Acting Injectable PrEP Among Transgender Women in the United States - (03/12/24)
     
  140. CROI: Real-World Use of Cabotegravir Long-Acting for Preexposure Prophylaxis: Trio Health Cohort - (03/12/24)
     
  141. CROI: Preexposure Prophylaxis With Cabotegravir Long-Acting Injectable in the OPERA Cohort - (03/12/24)
     
  142. CROI: No Virologic Failures, Good Safety With LA I njected CAB + RPV for Adolescents IMPAACT 2017 MOCHA Study - Mark Mascolini (03/11/24)
     
  143. CROI: High PrEP uptake and adherence with point of care tenofovir testing among young African women: Results from the INSIGHT cohort - (03/07/24)
     
  144. CROI: Final Results of ANRS 174 DOXYVAC: A Randomized trial to Prevent STIs in MSM on PrEP - (03/07/24)
     
  145. HIV Prevention Doubles PrEP Use: auto text messaging+mobile web-app peer support+non-maulaized telehealth coaching by paraprofessionals - (02/27/24)
     
  146. HIV pre-exposure prophylaxis provision by U.S. health centers in 2021 - (02/02/24)
     
  147. LAI PrEP Barriers & Facilitators US Primary Care Setting - (01/29/24)
     
  148. Lenacapavir Safety - Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial - (01/29/24)
     
  149. Lenacapavir 5 PrEP Global Studies - (01/29/24)
     
  150. CROI: ULTRA LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV
     
  151. CROI: Vaginal PrEP Efficacy of Biodegradable Islatravir Implants in Macaques Islatravir Implant Protects Macaques From Vaginal SHIV Infection - (02/24/23)
     
  152. 5 Purpose Studies for Lanacapavir PrEP: Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program - (01/10/24)
     
  153. Exploring barriers and facilitators to PrEP use among transgender women in two urban areas: implications for messaging and communication - (01/10/24)
     
  154. Out-of-pocket cost increase could put HIV prevention medications out of reach - (01/10/24)
     
  155. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial - (01/10/24)
     
  156. Brief Report: Outcomes of Individuals Using HIV Postexposure Prophylaxis-In-Pocket ("PIP") for Low-Frequency, High-Risk Exposures in Toronto, Canada - (01/10/24)
     
  157. TelePrEP in NYC - (01/10/24)
     
  158. Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness - (01/10/24)
     
  159. PrEP Use and HIV Incidence Among Youth At-Risk for HIV Infection in Los Angeles and New Orleans: Findings From ATN 149 - (01/10/24)
     
  160. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants - (01/10/24)
     
  161. Preexposure Prophylaxis Use History in People With Antiretroviral Resistance at Human Immunodeficiency Virus (HIV) Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022 - (01/10/24)
     
  162. HHS EHE (PrEP) Leaders Reflect on 2023 and Look Ahead to 2024 - (01/09/24)
     
  163. Understanding Psychosocial Determinants (Beliefs, Attitudes) of PrEP Uptake Among Cisgender Women Experiencing Heightened HIV Risk: Implications for Multi-Level Communication Intervention - (01/09/24)
     
  164. Advancing the community plan to end the HIV Epidemic in Philadelphia: a qualitative descriptive evaluation of low-threshold PrEP services in sexual health clinics - (01/09/24)
     
  165. 2 Studies on PrEP for Women IDUs, Demonstrate PrEP is a Necessary Tool for Women, to EtE - (01/09/24)
     
  166. Aging-Related Comorbidity Burden Among Women and Men With or At-Risk for HIV in the US, 2008-2019 - (01/08/24)
     
  167. Prioritising the values of potential users to promote uptake of HIV pre-exposure prophylaxis - (01/08/24)
     
  168. Person-centered HIV PrEP for cisgender women - (01/08/24)
     
  169. Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women - (01/08/24)
     
  170. Cocaine Eats Up Brain Twice as Fast as Normal Aging - (01/08/24)
     
  171. Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence - (01/08/24)
     
  172. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts - (01/08/24)
     
  173. ID Week: Update on PrEP Knowledge and Attitudes Among Adults Attending Public Health Clinics in Southern Arizona - (10/24/22)
     
  174. ID Week : Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis Into Standard of Care: Baseline Results From the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR) - (10/16/23)
     
  175. ID Week: High PrEP Awareness in US Women, But Only 20% Ever Used It - Mark Mascolini (10/23/22)
     
    176. ID Week : Increase in New HIV Diagnoses Following Decrease in Use of Pre-exposure Prophylaxis (PrEP) During the COVID-19 Pandemic - (10/16/23)
     
    Feasibility of Long-Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C. - (07/27/23)
     
    Presence of mental health concerns is associated with poor adherence in people taking pre-exposure prophylaxis in real-world clinical practice in the United States - (10/18/23)
     
    Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women - (10/16/23)
     
    IIntegrating Long-Acting Injectable Cabotegravir for PrEP Into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex With Men: Results From the PILLAR & EBONI Studies - (10/16/23)
     
    ID Week : Exploring Cisgender Women's HIV Pre-Exposure Prophylaxis (PrEP) Needs and Preferences Across Settings: the Role of Social-Structural Factors - (10/16/23)
     
    ID Week : Risk Factors, Risk Perception, and Long-Acting PrEP Awareness and Interest Among US Women: A National Survey - (10/16/23)
     
    ID Week : Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis Into Standard of Care: Baseline Results From the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR) - (10/16/23)
     
    ID Week : Acceptability of an HIV Pre-Exposure Prophylaxis (PrEP) Shared Decision-Making Tool (SDT) for Diverse Populations and Healthcare Providers - (10/13/23)
     
    At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implemtentation Science Trial - (10/13/23)
     
    The First Ten Years of HIV Preexposure Prophylaxis Use and Missed Opportunities at an Urban Academic Children's Hospital - (10/18/23)
     
    PEP-in-pocket (PIP): Long-term follow-up of on demand HIV post-exposure prophylaxis: Is PEP-in-Pocket Best Option for Low-Frequency High-Risk HIV Exposure? - (10/18/23)
     
    Only Half Prescribed CAB PrEP Get at Least 1 Shot in US Outpatient Network - (10/18/23)
     
    Expanding PrEP by Embedding Navigators in High STI Testing Clinical Sites - (10/18/23)
     
    Investing in National HIV PrEP Preparedness (Over-the-Counter free PrEP) - (09/28/23)
     
    Free the PrEP - Over-the-Counter Access to HIV Preexposure Prophylaxis - (08/11/23)
     
    IAS: PrEP Equity by sex and age, United States, 2012-2021 - (08/14/23)
     
    Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California
     
    ID Week: Predicted uptake of novel HIV treatment options in the United States - (10/16/23)
     
    ID Week : Factors driving decisions in the use of HIV Pre-Exposure Prophylaxis: Data from a real-world study in the United States - (10/16/23)
     
    ID Week : The Real-World Impact of Pre-Exposure Prophylaxis (PrEP) Prescription Uptake and Dispensing Status on HIV Infection Risk in the US - (10/16/23)
     
    ID Week : Evaluating Pre-Exposure Prophylaxis Use in a Large Integrated Rural US Health System - (10/16/23)
     
    ID Week : Facilitators and Barriers to Engaging in PrEP and Gender Affirming Therapy for Black and Latina Transgender Women in South Florida - (10/16/23)